Avingtrans investee Adaptix receives 10(k) clearance from FDA

Avingtrans PLC (LON:AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, announces that medical imaging technology associate company Adaptix Limited (Adaptix) has received 510(k) clearance from the U.S. Food and Drug Administration for its first orthopaedic medical imaging product.

The Board of Adaptix has made the following announcement:

Adaptix, based at Oxford University Science Park, has received 510(k) clearance for its first medical imaging product. The first Adaptix medical product is a Digital Tomosynthesis Orthopaedic imaging system. It is a portable, low-dose imaging system capable of delivering fast, lower-cost, X-ray imaging at the point of patient care. Developed specifically to offer 3D X-ray imaging of hands, elbows and feet at a fraction of the radiation dose and per-study price of traditional CT systems, the system provides clinicians with clearer images than 2D X-ray systems, offering advantages in terms of fewer acquisitions, accelerated patient workflow and enhanced diagnostic accuracy.

Adaptix is already serving veterinary and industrial (Non-Destructive Evaluation) markets using its novel and patent-protected technologies. Receiving the 510(k) clearance is important as it is the first step in Adaptix delivering its mission to transform radiology through provision of innovative truly-portable 3D imaging technologies into healthcare providers.

Mark Evans, CEO of Adaptix, commented:

“We are delighted to receive the 510(k) clearance which allows this innovative technology, and our first medical product, to be marketed in the world’s largest healthcare market. The team are energized by achieving this milestone, and we look forward to delivering enhanced orthopaedic DT imaging systems; a dental DT imaging system; and a chest DT imaging system for Intensive Care and Emergency Department use. We see a future where 3D travels to the patient at the point-of-care throughout hospitals, clinics and primary care transforming patient pathways, improving patient experience, and reducing the cost of care delivery.”

In 2021, Avingtrans invested £4m in Adaptix, for an 11.9% stake in the business and in December 2022 announced a further investment of £2m by means of a Convertible Loan.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    Avingtrans

    More articles like this

    Avingtrans

    Avingtrans looking to strengthen the portfolio further (LON:AVG)

    Avingtrans’ Steve McQuillan discusses interim results, the performance of the main divisions, their medical division, stronger than average order book and what investors can expect in the coming year from the company in this exclusive interview with DirectorsTalk.

    Avingtrans

    Avingtrans appoints Willem Baralt as its new Chairman

    Avingtrans PLC (LON:AVG) has announced that further to the statement made on 14 December 2022, Adaptix, the Oxford based emerging MedTech Company, has appointed Willem Baralt as its new Chairman. Willem, previously of Quanta Dialysis Technologies, will succeed

    Avingtrans

    Avingtrans ownership in Magnetica will increase to 74%

    Avingtrans PLC (LON:AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, has announced that shareholders of Magnetica have approved an increase to Avingtrans’ ownership as part of a capital

    Avingtrans

    Avingtrans acquires the business and assets of Hevac

    Avingtrans PLC (LON:AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, has announced that trading in the first 6 months of the financial year to 30 November 2022 was

    Avingtrans

    Avingtrans deliver solid results and a confident outlook (VIDEO)

    Avingtrans PLC (LON:AVG) CEO Steve McQuillan joins DirectorsTalk Interviews to discuss its results for the year ended 31st May 2022. Steve talks us through the highlights, the performance and highlights in the Energy division, involvement in the Medical division,

    Avingtrans

    Avingtrans revenue from continuing operations increased by 1.9% to £100.4m

    Avingtrans PLC (LON:AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, has announced its preliminary results for the year ended 31 May 2022. Financial Highlights ·      Revenue from

    Avingtrans

    Avingtrans’ Hayward Tyler awarded $7m nuclear contracts

    Avingtrans PLC (LON:AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, has announced Hayward Tyler, Inc has secured two new nuclear contracts worth a total of US

    Avingtrans

    Avingtrans results, visibility and M&A opportunities (Interview)

    Avingtrans PLC (LON:AVG) CEO Steve McQuillan joins DirectorsTalk Interviews to discuss its interim results for the six months ended 30 November 2021. Steve talks us through the highlights, its strong order book, updates us on the developments with Hayward

    Avingtrans

    Avingtrans’ PIE strategy continues to deliver robust results

    Avingtrans PLC (LON:AVG), the international engineering group which designs, manufactures and supplies original equipment, systems and associated aftermarket services to the energy, medical and industrial sectors, has announced its interim results for the six months ended 30 November

    Avingtrans

    Avingtrans appoints Jo Reedman as an independent Non-Executive Director

    Avingtrans PLC (LON:AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, has announced the appointment of Jo Reedman, as an independent Non-Executive Director, effective on 1st March 2022.

    Avingtrans

    Booth welcomes HS2 CEO for site visit

    Booth Industries was delighted to welcome HS2 CEO Mark Thurston yesterday, to view its new purpose-built facility for the manufacture of safety doors for HS2 tunnels and meet staff working on the project. The £36.5million 10-year contract was

    No more posts to show